Skip to Content
Merck
All Photos(1)

Key Documents

SML2514

Sigma-Aldrich

Nedaplatin

Synonym(s):

Nedaplatin, Cis-Diammine (Glycolato)Platinum

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C2H8N2O3Pt
CAS Number:
95734-82-0
Molecular Weight:
303.17
UNSPSC Code:
12352200
NACRES:
NA.77

form

powder

storage temp.

2-8°C

InChI

1S/C2H4O3.2H2N.Pt/c3-1-2(4)5;;;/h3H,1H2,(H,4,5);2*1H2;/q;2*-1;+2

InChI key

KLNFSAOEKUDMFA-UHFFFAOYSA-N

Biochem/physiol Actions

Nedaplatin is a second-generation cisplatin analog with antineoplastic activity. Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand, nedaplatin forms reactive platinum complexes that bind to nucelophillic groups in DNA, resulting in intrastrand and interstrand DNA cross-links, apoptosis and cell death. Nedplatin is less nephrotoxic and neurotoxic compared to both cisplatin and carboplatin.

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Classifications

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1B - Skin Irrit. 2 - Skin Sens. 1B - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jun Fu et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 25(4), 1707-1713 (2020-10-26)
To investigate the efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer (SCLC). 64 patients diagnosed with SCLC in our hospital from April 2013 to June 2015 were retrospectively analyzed. Thirty-two patients in
Hongmei Zhang et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 25(1), 80-86 (2020-04-12)
To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. A total of 100 ovarian cancer patients treated in our hospital from January 2015 to
Takuma Kagami et al.
BMC cancer, 20(1), 1123-1123 (2020-11-22)
Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognostic value of SLFN11 expression in esophageal squamous cell carcinoma
Haruka Miyata et al.
Japanese journal of clinical oncology, 50(5), 609-616 (2020-01-20)
Bladder-preserving trimodal therapy is recognized as a promising alternative treatment for muscle-invasive bladder cancer. We report the updated outcomes of muscle-invasive bladder cancer patients that were treated using our treatment protocol, which involves radiotherapy delivered with a real-time tumor-tracking radiotherapy
Osamu Maeda et al.
Anticancer research, 40(5), 2497-2507 (2020-05-06)
Spectrin αII contributes to cisplatin and carboplatin resistance in ovarian serous carcinoma cells, and its expression in surgical specimens is a valid predictor of prognosis. We sought to identify effective drugs for spectrin αII-mediated cisplatin-resistant cells. We employed SKOV3 cells
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service